Phase 3 N=3,388 Safety Study of ProQuad® rHA in Infants (V221-037)
Measles · Mumps · Rubella
Primary: Percentage of Participants Experiencing an Adverse Event (AE) After ProQuad® Dose 2 — 57.66 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition
Postpartum Depression
Primary: Blood-oxygen-level-dependent (BOLD) Response During Functional Magnetic Resonance Imaging (fMRI) z Statistic — 2.3; 2.0; 2.1; 1.7 z score — p=.27
Phase 2 N=18 The Effect of Glutamatergic Modulation on Cocaine Self-administration
Cocaine Dependence
Primary: Number of Choices to Self-administer Cocaine (Out of 5 Choices) — 1.61; 4.33 number of cocaine choices
Phase 2 N=43 Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
HIV Infections
Primary: Proportion of Participants Who Developed Grade 3 or 4 Adverse Events Attributed to the Study Treatment. — 0.17; 0.1; 0.19 proportion of participants
Phase 2 N=32 A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
HER-2 Positive Breast Cancer
Primary: Intracranial Objective Response Rate- Modified RECIST Criteria — 0; 1; 17; 8 Participants
N/A N=300 Evaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Delta
Liver Cancer
Primary: Serum Aflatoxin Level in Liver Cancer Patients — 7.96; 6.10; 4.13 ng\ml
Phase 3 N=388 Dysport® Adult Lower Limb Spasticity Study
Leg Spasticity
Primary: Least Squares Mean Change From Baseline to Week 4 in the MAS Score in the Gastrocnemius-soleus Complex (GSC) (Knee Extended) — -0.6; -0.8; -0.5 units on a scale…
N/A N=41 Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
Polycystic Ovary Syndrome
Primary: 17-hydroxyprogesterone Responses to hCG in PCOS Women and Normal Controls — 1.3; 3; 1.1 ng/ml
N/A N=40 Clarithromycin as Adjuvant to Periodontal Debridement
Aggressive Periodontitis
Primary: Clinical Attachment Level — 2.71; 3.03 milimeter
Phase 4 N=61 Combination Treatment Study for Memory Impairment and Depression
Depression · Mild Cognitive Impairment
Primary: Selective Reminding Test (SRT) Total Recall — 45.6; 46.6 Words
N/A N=36,573 Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe
Atrial Fibrillation
Primary: Percentage of Participants With Potential Off-label Use Estimated Among New Users of Dabigatran Etexilate in Each of the Data Sources. — 24.1; 34.0; 17.1; 5.7 percentage…
Phase 2 N=150 A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease
Crohn's Disease
Primary: Adjudicated Potential Cardiovascular Events — 0 Number of events meeting criteria
Phase 2 N=42 Safety Escalating Repeat IV, in Stroke Patients
Ischaemic Attack, Transient
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 11; 6; 8; 6 Participants
Phase 2 N=6 A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
Diabetes Mellitus, Type 2
Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) (Part A) — 0; 0 Participants
Phase 2 N=6 Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
DIRA
Primary: Number of Subjects Who Maintained Inflammatory Remission With Rilonacept — 6 Participants